纳武利尤单抗对比伊匹木单抗辅助治疗(CheckMate 238试验):按AJCC第8版分期标准重新评估III期黑色素瘤患者的4年疗效结局
CheckMate 238双盲3期试验纳入按AJCC第7版分期为IIIB、IIIC或IV期已切除黑色素瘤患者,随机接受纳武利尤单抗或伊匹木单抗辅助治疗。按AJCC第8版重新分析,至少随访4年后,纳武利尤单抗在III期患者中的无复发生存和远处转移无生存优势与AJCC第7版结果一致。
要点
- 按AJCC第8版分析,纳武利尤单抗对比伊匹木单抗在已切除III期黑色素瘤中的优效性得以保持。
- AJCC第7版或第8版分期标准下,III期各亚期之间的无复发生存风险比均无统计学显著差异。
- CheckMate 238的4年无复发生存和远处转移无生存结局在AJCC第7版与第8版分期标准下一致。
核心结论
- CheckMate 238的4年无复发生存和远处转移无生存结局在AJCC第7版与第8版分期标准下一致,因此结局获益可外推至按AJCC第8版诊断的患者。
研究设计与样本
- 双盲3期试验(NCT02388906),纳入年龄≥15岁、经组织学确认的AJCC第7版IIIB、IIIC或IV期已切除黑色素瘤患者。
- 患者随机接受纳武利尤单抗3 mg/kg每2周静脉给药或伊匹木单抗10 mg/kg每3周静脉给药4次后每12周给药,两者均≤1年。
- 在III期疾病患者中按AJCC第7版和第8版评估无复发生存和远处转移无生存。
主要发现
- 按AJCC第7版分期,分别有42.4%和57.3%的患者处于IIIB和IIIC亚期;按AJCC第8版,分别有1.1%、30.4%、62.8%和5.0%的患者处于IIIA、IIIB、IIIC和IIID亚期。
- 至少随访4年后,按AJCC第8版分析,纳武利尤单抗对比伊匹木单抗在已切除III期黑色素瘤患者中的优效性得以保持。
- 按AJCC第7版或第8版分期标准,III期各亚期之间的无复发生存风险比均无统计学显著差异(交互检验:AJCC第7版P=0.8115;AJCC第8版P=0.1051;远处转移无生存分别为P=0.8392(AJCC第7版)和P=0.8678(AJCC第8版))。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8. PATIENTS AND METHODS: In a double-blind, phase 3 trial (NCT02388906), patients aged ≥15 years with resected, histologically confirmed AJCC-7 stage IIIB, IIIC, or IV melanoma were randomised to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, both intravenously ≤1 year. Recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were assessed in patients with stage III disease, per AJCC-7 and AJCC-8. RESULTS: Per AJCC-7 staging, 42.4% and 57.3% of patients were in substage IIIB and IIIC, respectively; per AJCC-8, 1.1%, 30.4%, 62.8%, and 5.0% were in IIIA, IIIB, IIIC, and IIID. After 4 years' minimum follow-up, the AJCC-7 superior efficacy of nivolumab over ipilimumab in patients with resected stage III melanoma was preserved per AJCC-8 analysis. No statistically significant difference in RFS between stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria (interaction test: AJCC-7, P = 0.8115; AJCC-8, P = 0.1051; P = 0.8392 ((AJCC-7) and P = 0.8678 (AJCC-8) for DMFS). CONCLUSIONS: CheckMate 238 4-year RFS and DMFS outcomes are consistent per AJCC-7 and AJCC-8 staging criteria. Outcome benefits can therefore be translated for patients diagnosed per AJCC-8.
引用
- Larkin J, Weber J, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer. 2022. PMID: 35964471. doi:10.1016/j.ejca.2022.06.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。